The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders i: Parkinson's disease

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 2, 2011, Pages 239-250

  Campos, Helineide Cristina ^a   Rocha, Miguel Divino da ^a   Viegas, Flávia Pereira Dias ^a   Nicastro, Patrícia Carolina ^a   Fossaluzza, Poliana Calve ^a   Fraga, Carlos Alberto Manssour ^b   Barreiro, Eliezer J ^b   Viegas, Claudio ^a  

^a FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Alzheime sdisease; Biodiversity; Chemistry; Drugdiscovery; Medicinal; Naturalproducts; Neurodegenerative disorders; Parkinso sdisease

Indexed keywords

HERBACEOUS AGENT; NATURAL PRODUCT; PLANT EXTRACT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COGNITION; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG RESEARCH; DRUG STRUCTURE; HERB; HUMAN; HUNTINGTON CHOREA; MEDICINAL PLANT; MEMORY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE;

EID: 79551664192     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152711794480483     Document Type: Article

References (146)

1. Viegas Jr., C.; Bolzani, V.S.; Barreiro, E.J. The natural products and the modern medicinal chemistry. Quim. Nova, 2006, 29, 326-337.
2. Cragg, G.M.; Newmann, D.J.; Snader, K.M. Natural products in drug discovery and development. J. Nat. Prod., 1997, 60, 52-60.
3. Cragg, G.M.; Newmann, D.J.; Snader, K.M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66, 1022-1037.
4. Newmann, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477.
5. Newmann, D.J. Natural products as leads to Potential Drugs: An old process or the new hope for drug discovery? J. Med. Chem., 2008, 51(9), 2589-2599.
6. Ojima, I. Modern natural products chemistry and drug discovery. J. Med. Chem., 2008, 51(9), 2587-2588.
7. Booth, R.G.; Neumeyer, J.L. Drugs used to treat neuromuscular disorders: antiparkinsonian and spasmolytic agents. Williams, D. A.; Lemke, T.L., Eds.; In: Foyes Principles of Medicinal Chemistry. 5th ed., Lippincott Williams & Wilkins: United States, 2002, pp. 480-493.
8. Bolzani V.S., Furlan M., Fraga C.A.M., Barreiro E.J. Produtos naturais como candidatos a fármacos úteis no tratamento do Mal de Alzheimer. Quím. Nova, 2004, 27(4), 655-660.
9. Bolzani, V.S.; Barreiro, E.J.; Fraga, C.A.M. New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors. Mini Rev. Med. Chem., 2005, 5, 915-926.
10. Rocha, M.D.; Viegas, F.P.D.; Campos, H.C.; Nicastro, P.C.; Fossaluzza, P.C.; Fraga, C.A.M.; Barreiro, E.J.; Viegas Jr., C. The role of natural products In the discovery of new drug candidates for the treatment of Neurodegenative disorders II: Alzheimer's Disease. CNS Neurol. Dis. Drug Target 2010, 10(2), 252-271.
11. Carlini, E.A. Plants and the central nervous system. Pharmacol. Biochem. Behav., 2003, 75, 501-512. b) Grunze, H.; Langosch, J.; Schirrmacher, K.; Bingmann, D.; Von Wegerer, J.; Walden, J. Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar top established mood stabilizers-a review. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2001, 25, 1555-1570.
12. Grunze, H.; Langosch, J.; Schirrmacher, K.; Bingmann, D.; Von Wegerer, J.; Walden, J. Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar top established mood stabilizers-a review. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2001, 25, 1555-1570
13. Eisenberg, D.M.; Kessler, R.C.; Foster, C.; Norlock, F.E.; Calkins, D.R.; Delbanco, T.L. Unconventional medicine in the United States. N. Engl. J. Med., 1993, 328, 246-252.
14. Speroni, E.; Billi, R.; Mercati, V.; Boncompagni, E.; Toja, E. Sedative effects of crude extract of Passiflora incarnata after oral administration. Phytother. Res., 1996, 10, S92-S94
15. Soulimani, R.; Younos, C.; Jarmouni, S.; Bousta, D.; Misslin, R.; Mortier, F. Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. J. Ethnopharmacol., 1997, 57, 11-20.
16. Dhawan, K.; Kumar, S.; Sharma, A. Anti-anxiety studies on extracts of Passiflora incarnate Linneaus. J. Ethnopharmacol., 2001, 78, 165-170.
17. Kennedy, D.O.; Scholey, A.B. Ginseng: potential for the enhancement of cognitive performance and mood. Pharmacol. Biochem. Behav., 2003, 75, 687-700.
18. Radad, K.; Gille, G.; Liu, L.; Rausch, W.-D. Use of Ginseng in medicine with emphasis on neurodegenerative disorders. J. Pharmacol. Sci., 2006, 100, 175-186.
19. Dewick, P.M. Medicinal Natural Products: A Biosynthetic Approach; John Wiley & Sons; New York, 1997.
20. Wen, T-C.; Yoshimura, H.; Matsuda, S.; Lim, J.-H.; Sakanaka, M. Ginseng root prevents learning disability and neuronal loss in gerbils with 5-minute forebrain ischemia. Acta Neuropathol., 1996, 91, 15-22.
21. Zhang, Y.G.; Liu, T.P. Influences of ginsenosides Rb1 and Rg1 on reversible focal brain ischemia in rats. Acta Pharmacol. Sin., 1996, 17(1), 44-48.
22. Kim, Y.C.; Kim, S.R.; Markelonis, G.J.; Oh, T.H. Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamateinduced neurodegeneration. J. Neurosci. Res., 1998, 4, 426-432.
23. Liao, B.; Newmark, H. Zhou, R. Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg3 on spinal cord neurons in vitro. Exp. Neurol., 2002, 173, 224-234.
24. Byun, B.H.; Shin, I.; Yoon, Y.S.; Kim, S.I.; Joe, C.O. Modulation of protein kinase C activity in NIH 3T3 cells by plant glycosides from Panax ginseng. Planta Medica, 1997, 63, 389-392.
25. Liberti, L.E.; Der Mardesian, A. Evaluation of commercial Ginseng products. J. Pharm. Sci., 1978, 10, 1487-1489.
26. Phillipson, J.D.; Anderson, L.A. Ginseng-quality safety and efficacy? Pharm. J., 1984, 232, 161-165.
27. Soldati, F.; Sticher, O. HPLC separation and quantitative determination of ginsenosides from Panax ginseng, Panax quinquefolium and from ginseng drug preparations. Planta Medica, 1980, 39(4), 348-357.
28. Kennedy, D.O.; Scholey, A.B.; Wesnes, K.A. The dose dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology, 2000, 151, 416-423.
29. Kennedy, D.O.; Scholey, A.B.; Wesnes, K.A. Differential, dosedependent changes in cognitive performance and mood following acute administration of Ginseng to healthy young volunteers. Nutr. Neurosci., 2000, 4(4), 295-310.
30. Kennedy, D.O.; Scholey, A.B.; Wesnes, K.A. Differential, dosedependent changes in cognitive performance following acute administration of ginkgo biloba/Panax ginseng combination to healthy young volunteers. Nutr. Neurosci., 2001, 4(5), 399-412.
31. Kennedy, D.O.; Scholey, A.B.; Wesnes, K.A. Modulation of cognition and mood following administration of single doses of Ginkgo biloba, Ginseng and a Ginkgo/Ginseng combination to healthy young adults. Physiol. Behav., 2002, 75, 1-13.
32. Kennedy, D.O.; Scholey, A.B.; Tildesley, N.T.J.; Perry, E.K.; Wesnes, K.A. Modulation of mood and cognitiver performance following acute administration of single doses of Melissa officinalis (Lemon Balm). Pharmacol. Biochem. Behav., 2002, 72(4), 953-964.
33. Kennedy, D.; Scholey, A.B.; Drewery, L.; Marsh, R.; Moore, B.; Ashton, H. Topographic, E.E.G effects of single doses of Panax ginseng and Ginkgo biloba. Pharmacol. Biochem. Behav., 2003, 75, 701-709.
34. Wesnes, K.A.; Ward, T.; McGinty, A.; Petrini, O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle aged volunteers. Psychopharmacology, 2000, 152, 353-361.
35. Sünram-Lea, S.I.; Birchall, R.J.; Wesnes, K.A.; Petrini, O. The effect of acute administration of 400mg of Panax ginseng on cognitive performance and mood in healthy young volunteers. Curr. Top. Nutraceutical Res., 2005, 3, 65-74.
36. Gibb, W.R. Neuropathology of Parkinson's disease and related syndromes. Neurol. Clin., 1992, 10, 361-376.
37. Olney, J.W. Brain lesions, obesity, and other disturbances in mice related with monosodium glutamate. Science, 1969, 164, 719-721.
38. Lipton, S.A.; Rosenberg, P.A. Excitatory amino acids as a final common pathway for neurologic disorders. New Engl. J. Med., 1994, 330, 613-622.
39. Wallace D.C. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science, 1992, 256, 628-632.
40. Schapira, A.H.; Mann, V.M.; Cooper, J.M.; Dexter, D.; Daniel, S.E.; Jenner, P.; Clark, J.B.; Marsden, C.D. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem., 1990, 55, 2142-2145.
41. D.G.; Young, A.H. In: Treatment of Central Nervous System Degenerative Disorders. Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 9th Ed.; McGraw Hill; New York, 1996, pp. 503-519.
42. Bushnell, D.M.; Martin, M.L. Quality of life and Parkinson's disease: Translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39). Qual. Life Res., 1999, 8, 345-350. b) Savitt, J.M.; Dawson, V.L.; Dawson, T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest., 2006, 116, 1744-1754.
43. Dorsey, E.R.; Constantinescu, R.; Thompson, J.P.; Biglan, K.M.; Holloway, R.G.; Kieburtz, K.; Marshall, F.J.; Ravina, B.M.; Schifitto, G.; Siderowf, A.; Tanner, C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 2007, 68, 384-386.
44. Cardoso, S.M.; Moreira, P.I.; Agostinho, P.; Pereira, C.; Oliveira, C.R. Neurodegenerative pathways in Parkinson's disease: Therapeutic strategies. CNS Neurol. Dis. Drug Targets, 2005, 4, 405-419.
45. Miller, R.L.; James-Kracke, M.; Sun, G.Y.; Sun, A.Y. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem. Res., 2009, 34, 55.
46. Dauer, W.; Przedborski, S. Parkinson's disease: mechanisms and models. Neuron, 2003, 39, 889-909.
47. Samii, A.; Nutt, J.G.; Ransom, B.R. Parkinson's disease. Lancet, 2004, 363, 1783-1793.
48. Moreira, P.I.; Siedlak, S.L.; Aliev, G.; Zhu, X.; Cash, A.D.; Smith, M.A.; Perry, G. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J. Neural Transm., 2005, 112, 921-932.
49. Poirier, L.J.; Sourkes, T.L. Influence of the substantia nigra on the catecholamine content of the striatum. Brain, 1965, 88, 181-192.
50. Beal, M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr., 2004, 36, 381-386.
51. Abekawa, T.; Ohmori, T.; koyama, T. Effect of NO synthesis inhibition on striatal dopamine release and stereotyped behaviour induced by a single administration of methamphetamine. Progress Neuro-Psychopharmacol. Biol. Psychiatry, 1997, 21, 831-838.
52. Gonzales-Hernandez, T.; Perez de la Cruz, M.A.; Mantolan-Sarmiento, B. Histochemical and immunohistochemical detection of neurons that produce nitric oxide: effect of different fixative parameters and immunoreactivity against non-neuronal NOS antisera. J. Histochem. Cytochem., 1996, 44, 1399-1413.
53. Gao, H.M.; Hong, J.S.; Zhang, W.; Liu, B. Synergisitc dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J. Neurosci., 2003, 23, 1228-1236.
54. Gao, H.M.; Liu, B.; Zhang, W.; Hong, J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's diseasae. FASEB J. 2003, 17, 1954-1956.
55. Mander, P.K.; Jekabsone, A.; Brown, G.C. Microglia proliferation in regulated by hydrogen peroxide from NADPH oxidase. J. Immunol., 2006, 176, 1046-1052.
56. Brooks, A.I.; Chadwick, C.A.; Gelbard, H.A.; Cory-Slechta, D.A.; Federoff, H.J. Paraquat elicited neurobehavioural síndrome caused by dopaminergic neuron loss. Brain Res., 1999, 823, 1-10.
57. Liou, H.H.; Tsai, M.C.; Chen, C.J.; Jeng, J.S.; Chang, Y.C.; Chen, S.Y.; Chen, R.C. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology, 1997, 48(6), 1583-1588.
58. Yang, W.L.; Sun, A.Y. Paraquat-induced cell death in PC12 cells. Neurochem. Res., 1998, 23, 1387-1394.
59. Koshimura, I.; Imai, H.; Hidano, T.; Endo, K.; Mochizuki, H.; Kondo, T.; Mizuno, Y. Dimethoxyphenylethylamine and tetrahydropapaverine are toxic to the nigrostriatal system. Brain Res., 1997, 773, 108-116.
60. Benedetto, A.; Au, C.; Aschner, M. Manganese-induced dopaminergic neurodegeneration: insights into mechanisms and genetics shared with Parkinson's disease. Chem. Rev., 2009, 109, 4862-4884.
61. Li, X.; Sun, A.Y. Paraquat induced activation of transcription factor AP-1 and apoptosis in PC12 cells. J. Neur. Trans., 1999, 106, 1-21.
62. Yang, W.; Sun, A.Y. Paraquat-induced free radical reaction in mouse brain microsomes. Neurochem. Res., 1998, 23, 47-53.
63. Schober, A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res., 2004, 318, 215-224.
64. Lim, M.L.; Mercer, L.D.; Nagley, P.; Beart, P.M. Rotenone and MPP+ preferentially redistribute apoptosis-inducing factor in apoptotic dopamine neurons. Neuroreport, 2007, 18, 307-312.
65. Poskanzer, D.C.; Schwab, R.S. Cohort analysis of Parkinson's síndrome: evidence for a single etiology related to subclinical infection about 1920. J. Chronic Dis., 1963, 16, 961-973.
66. Reid, A.H.; McCall, S.; Henry, J.M.; Taubenberger, J.K. Experimenting on the past: the enigma of von Economo's encephalitis lethargica. J. Neuropathol. Exp. Neurol., 2001, 60, 663-670.
67. Firestone, J.A.; Smith-Weller, T.; Franklin, G.; Swanson, P.; Lonstreth, W.T.; Checkoway, H. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch. Neurol., 2005, 62, 91-95.
68. Semchuk, K.M.; Love, E.J.; Lee, R.G. Parkinson's disease: A test of the multifactorial etiologic hypothesis. Neurology, 1993, 43, 1173-1180.
69. Yang, W-L.; Sun, A.Y. Paraquat-induced free radical reaction in mouce brain microsomes. Neurochem. Res., 1998, 23, 47-53.
70. Liou, H.H.; Tsai, M.C.; Chen, C.J.; Jeng, J.S.; Chang, Y.C.; Chen, S.Y.; Chen, R.C. Environmetnal risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology, 1997, 48, 1583-1588.
71. Jakel, R.J.; Kern, J.T.; Johnson, D.A.; Johnson, J.A. Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro. Toxicol. Sci., 2005, 87, 176-186.
72. Schober, A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res., 2004, 318, 215-224.
73. Landrigan, P.J.; Sonawane, B.; Butler, R.N.; Trasande, L.; Callan, R.; Droller, D. Early environmental origins of neurode-generative disease in later life. Environ. Health Persp., 2005, 113, 1230-1233.
74. Uversky, V.N. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res., 2004, 318, 225-241.
75. Thiruchelvam, M.; Richfield, E.K.; Baggs, R.B.; Tank, A.W.; Cory-Slechta, D.A. The Nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's Disease. J. Neurosci. Res., 2000, 20, 9207-9214.
76. Brooks, A.I.; Chadwick, C.A.; Gelbard, H.A.; Cory-Slechta, D.A.; Federoff, H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res., 1999, 823, 1-10.
77. Yang, W-L.; Sun, A.Y. Paraquat-induced cell death in PC12 cells. Neurochem. Res., 1998, 23, 1387-1394.
78. Shimizu, K.; Matsubara, K.; Ohtaki, K.; Shiono, H. Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture. Neurosci. Res., 2003, 46, 523-532.
79. Kang, D.; Miyako, K.; Kuribayashi, F.; Hasegawa, E. Changes of energy metabolism induced by 1-methyl-4-phenylpyridinium (MPP+)-related compounds in rat pheochromocytoma PC12 cells. Arch. Biochem. Biophys., 1997, 337, 75-80.
80. Chun, H.S.; Gibson, G.E.; DeGiorgio, L.A.; Zhang, H.; Kidd, V.J.; Son, J.H. Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J. Neurochem., 2001, 76, 1010-1021.
81. Peng, J.; Stevenson, F.F.; Doctrow, S.R.; Anderson, J.K. Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: implications for Parkinson's disease. J. Biol. Chem., 2005, 280, 29194-29198.
82. Yang, W.; Tiffany-Castiglioni, E. The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: relevance to the dopaminergic pathogenesis. J. Toxicol. Environ. Health Part A, 2005, 68, 1939-1961.
83. Thiruchelvam, M.; Prokopenko, O.; Cory-Slechta, D.; Richfield, E.; Buckley, B.; Mirochnitchenko, O. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype. J. Biol. Chem., 2005, 280, 22530-22539.
84. Shimizu, K.; Matsubara, K.; Ohtaki, K.; Fujimaru, S.; Saito, O.; Shiono, H. Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats. Brain Res., 2003, 976, 243-252.
85. Maguire-Zeiss, K.A.; Short, D.W.; Federoff, H.J. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? Brain Res. Mol. Brain Res., 2005, 134, 18-23.
86. Kotake, Y.; Ohta, S. MPP+ analogs acting on mitochondria and inducing neuro-degeneration. Curr. Med. Chem., 2003, 10, 2507-2516.
87. Mander, P.K.; Jekabsone, A.; Brown, G.C. Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase. J. Immunol., 2006, 176, 1046-1052.
88. Dringen, R. Oxidative and antioxidative potential of brain microglial cells. Antioxid. Redox Signal., 2005, 7, 1223-1233.
89. Scheller, C.; Sopper, S.; Jenuwein, M.; Neuen-Jacob, E.; Tatschner, T.; Grunblatt, E.; ter Meulen, V.; Riederer, P.; Koutsilieri, E. Early impairment in dopaminergic neurotransmission in brains of SIVinfected rhesus monkeys due to microglia activation. J. Neurochem., 2005, 95, 377-387.
90. Langston, J.W.; Forno, L.S.; Tetrud, J.; Reeves, A.G.; Kaplan, J.A.; Karluk, D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol., 1999, 46, 598-605.
91. Gao, H.M.; Hong, J.S.; Zhang, W.; Liu, B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci., 2002, 22, 782-790.
92. Casarejos, M.J.; Menendez, J.; Solano, R.M.; Rodríguez-Navarro, J.A.; Garcia de Yebenes, J.; Mena, M.A. Susceptibility to rotenone in increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem., 2006, 97, 934-946.
93. Nishimoto, S.; Nishida, E. MAPK signaling: ERK5 versus ERK1/2. EMBO Rep., 2006, 7, 782-786.
94. L. Mechanisms of MAPK signalling specificity Biochem. Soc. Trans. 2006, 34, 837-841.
95. Cushieri, J.; Maier, R.V. Mitogen-activated protein kinase (MAPK). Crit. Care Med., 2005, 33, S417-S419.
96. Kaminska, B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta, 2005, 1754, 253-262.
97. Uhlik, M.T.; Abell, A.N.; Cuevas, B.D.; Nakamura, K.; Johnson, G.L. Wiring diagrams of MAPK regulation by MEKK1, 2, and 3. Biochem. Cell Biol., 2004, 82, 658-663.
98. Wagey, R.; Hu, J.; Pelech, S.L.; Raymond, L.A.; Krieger, C. Modulation of NMDA-mediated excitotoxicity by protein kinase C. J. Neurochem., 2001, 78, 715-726.
99. Ran, X.; Miao, H-H.; Sheu, F-S.; Yan, D. Structural and dynamic characterization of a neuron-specific protein kinase C substrate, neurogranin. Biochemistry, 2003, 42, 5143-5150.
100. Catarsi, S.; Drapeau, P.J. Requirement for tyrosine phosphatase during serotonergic neuromodulation by protein kinase C. Neurosci. Res., 1997, 17, 5792-5797.
101. Ahlemeyer, B.; Kolker, S.; Zhu, Y.; Hoffmann, G.F.; Krieglstein, J. Increase in glutamate-induced neurotoxicity by activated astrocytes involves stimulation of protein kinase C. J. Neurochem., 2002, 82, 504-515.
102. Battaini, F. Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacol. Res., 2001, 44, 353-361.
103. Gallagher, H.C.; Murphy, K.J.; Foley, A.G.; Regan, C.M. Protein kinase C delta regulates neural cell adhesion molecule polysialylation state in the rat brain. J. Neurochem., 2001, 77, 425-434.
104. DeVries, T.A.; Neville, M.C.; Reyland, M.E. Nuclear import of PKC is required for apoptosis: identification of a novel nuclear import sequence. EMBO J., 2002, 21, 6050-6060.
105. Leverrier, S.; Vallentin, A.; Joubert, D. Positive feedback of protein kinase C proteolytic activation during apoptosis. Biochem. J., 2002, 368, 905-913.
106. Anantharam, V.; Kitazawa, M.; Wagner, J.; Kaul, S.; Kanthasamy, A.G. Caspase-3-dependent proteolytic cleavage of protein kinase C is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. J. Neurosci. Res., 2002, 22, 1738-1751.
107. Bey, E.A.; Xu, B.; Bhattacharjee, A.; Oldfield, C.M.; Zhao, X.; Li, Q.; Subbulakshmi, V.; Feldman, G.M.; Wientjes, F.B.; Cathcart, M.K. Protein kinase C is required for p47phox phosphorylation and translocation in activated human monocytes. J. Immunol., 2004, 173, 5730-5738.
108. He, R.; Nanamor, M.; Sang, H.; Yin, H.; Dinauer, M.C.; Ye, R.D. Reconstitution of chemotactic peptide-induced nicotinamide adenine dinucleotide phosphate (reduced) oxidase activation in transgenic COS-phox cells. J. Immunol., 2004, 173, 7462-7470.
109. Day, B.J.; Patel, M.; Calavetta, L.; Chang, L-Y.; Stamlet, J.S. A mechanism of paraquat toxicity involving nitric oxide synthase. Proc. Natl. Acad. Sci. USA, 1999, 96, 12760-12765.
110. Duval, D.L.; Miller, D.R.; Collier, J.; Billings, R.E. Characterization of hepatic nitric oxide synthase: identification as the cytokine-inducible form primarily regulated by oxidants. Mol. Pharmacol., 1996, 50, 277-284.
111. Margolis, A.S.; Porasumphatana, S.; Rosen, G.M. Role of paraquat in the uncoupling of nitric oxide synthase. Biochim. Biophys. Acta, 2000, 1524, 253-257.
112. Guo, Q.; Tirosh, O.; Packer, L. Inhibitory effect of ��-lipoic acid and its positively charged amide analogue on nitric oxide production in RAW 264.7 macrophages. Biochem. Pharmacol., 2001, 61, 547-554.
113. Shih, C-L.; Chi, S-I.; Chiu, T.H.; Sun, G.Y.; Lin, T-N. Ethanol effects on nitric oxide production in cerebral pial cultures. Alcohol Clin. Exp. Res., 2001, 25, 612-618.
114. Connely, L.; Madhani, M.; Hobbs, A.J. A pro-inflammatory role for eNOS-derived NO in vivo. J. Biol. Chem., 2005, 280, 10040-10046.
115. Xia, J.; Simonyi, A.S.; Sun, G.Y. Chronic ethanol and iron administration on iron content, neuronal nitric oxide synthase, and superoxide dismutase in rat cerebellum. Alcohol Clin. Exp. Res., 1999, 23, 702-707.
116. Gobbel, G.T.; Chan, TY-Y.; Chan, P.H. Nitric oxide-and superoxide-mediated toxicity in cerebral endothelial cells. J. Pharmacol. Exp. Ther., 1997, 282, 1600-1607.
117. Tomita, M.; Okuyama, T.; Ishikawa, T.; Hidaka, K.; Nohno, T. The role of nitric oxide in paraquat-induced cytotoxicity in the human A549 lung carcinoma cell line. Free Radic. Res., 2001, 34, 193-202.
118. Shin, C.Y.; Choi, J-W.; Jang, E.S.; Ju, C.; Kim, W-K.; Kim, H-C; Choi, C-R.; Ko, K.H. Dehydroepiandrosterone inhibits the death of immunostimulated rat C6 glioma cells deprived of glucose. Brain Res., 2001, 922, 267-275.
119. Yamamoto, F.; Ohgari, Y.; Yamaki, N.; Kitajima, S.; Shimokawa, O.; Matsui, H.; Taketani, S. The role of nitric oxide in δ-aminolevulinic acid (ALA)-induced photosensitivity of cancerous cells. Biochem.Biophys. Res. Commun., 2007, 353, 541-546.
120. Goralski, K.B.; Renton, K.W. Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats. Toxicol. Appl. Pharmacol., 2004, 196, 381-389.
121. Schroeder, K.; Sweet, M.J.; Hume, D.A. Signal integration between IF γ and TLR signalling pathways in macrophages. Immunobiology, 2006, 211, 511-524.
122. Obeso, J.A.; Rodriguez-Oroz, M.C.; Goetz, C.G.; Marin, C.; Kordower, J.H.; Rodriguez, M.; Hirsch, E.C.; Farrer, M.; Schapira, A.H.V.; Halliday, G. Missing pieces in the Parkinson's disease puzzle. Nat. Med., 2010, 16, 653-661.
123. Khanna, S.; Park, H-A.; Sen, C.K.; Golakoti, T.; Sengupta, K.; Venkateswarlu, S.; Roy, S. Neuroprotective and anti-inflammatory properties of a novel demethylated curcuminoid. Antioxid. Redox. Signal., 2009, 11(3), 449-468.
124. Chan, M.M.Y.; Huang, H.I.; Fenton, M.R.; Fong, D. In vivo inhibition of nitric oxide synthase gene expression by curcumin in gene expression by curcumin, and cancer prevention natural product with anti-inflammatory properties. Biochem. Pharmacol., 1998, 55, 1955.
125. Hasegawa, K.; Naiki, M.; Yamada, J. Curcumin has potent antiamyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuroscience, 2004, 75, 742-750.
126. Rajeswari A.; Sabesan, M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology, 2008, 16, 96-99.
127. Rocha-González, H.I.; Ambriz-Tututi, M.; Granados-Soto, V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci. Ther., 2008, 14, 234-247.
128. Nonomura, S.; Kanagawa, H.; Makimoto, A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jokon (Polygonum cuspidatum Sieb. Et Zucc.). Yakugaku Zasshi, 1963, 83, 983-988.
129. Tokusoglu, O.; Unal, M.K.; Yemis, F. Determination of the phytoalexin resveratrol (3,5,4'-trihydroxystilbene) in peanuts and pistachios by high-performance liquid chromatographic diode array (HPLC-DAD) and gas chromatography-mass spectrometry (CGMS). J. Agric. Food Chem., 2005, 53, 5003-5009.
130. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
131. Ribeiro de Lima, M.T.; Waffo-Téguo, P.; Teissedre, P.L.; Pujolas, A.; Vercauteren, J.; Cabanis, J.C.; Mérillon, J.M. Determination of stilbenes (trans-astrigin, cis-and trans-piceid, and cis-and transresveratrol) in Portuguese wines. J. Agric. Food Chem., 1999, 47, 2666-2670.
132. Frémont, L. Biological effects of resveratrol. Life Sci., 2000, 66, 663-673.
133. Granados-Soto, V. Pleiotropic effects of resveratrol. Drug News Perspect., 2003, 16, 299-307.
134. Ramassamy, C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. Eur. J. Pharmacol., 2006, 545, 51-64.
135. Singh, N.; Pillay, V.; Choonara, Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol., 2007, 81, 29-44.
136. Jellinger, K.; Kienzl, E.; Rumpelmair, G.; Riederer, P.; Stachelberger, H.; Ben-Shachar, D.; Youdim, M.B. Neuromelanin and nigrostriatal dopamine neuron degeneration. J. Neurochem., 1993, 60, 1976-1977.
137. Lee, M.K.; Kang, S.J.; Poncz, M.; Song, K.J.; Park, K.S. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp. Mol. Med., 2007, 39, 376-384.
138. Chalimoniuk, M.; Glowacka, J.; Zabielna, A.; Eckert, A.; Strosznajder, J.B. Nitric oxide alters arachidonic acid turnover in brain cortex synaptoneurosomes. Neurochem. Int., 2006, 48, 1-8.
139. Dore, S. Unique properties of polyphenol stilbenes in the brain: More than direct antioxidant actions; gene/protein regulatory activity. Neurosignals, 2005, 14, 61-70.
140. Esposito, E.; Rotilio, D.; Di Matteo, V.; Di Giulio, C.; Cacchio, M.; Algeri, S. A review of specific dietary antioxidants and the effects on biochemical mechanisms realted to neurodegenerative processes. Neurobiol. Aging, 2002, 23, 719-735.
141. Simonyi, A.; Woods, D.; Sun, A.Y.; Sun, G.Y. Grape polyphenols inhibit chronic ethanol-induced COX-2 mRNA expression in rat brain. Alcohol Clin. Exp. Res., 2002, 26, 352-357.
142. Sun, G.Y.; Xia, J.; Draczynska-Lusiak, B.; Simonyi, A.; Sun, A.Y. Grape polyphenols protect neurodegenerative changes induced by chronic ethanol administration. Neuroreport, 1999, 10, 93-96.
143. Sun, G.Y.; Xia, J.; Xu, J.; Allenbrand, B.; Simonyi, A.; Rudeen, P.K. Dietary supplementation of grape polyphenols to rats ameliorates chronic etanol-induced changes in hepatic morphology without altering changes in hepatic lipids. J. Nutr., 1999, 129, 1814-1819.
144. Chanvitayapongs, S.; Draczynska-Lusiak, B.; Sun, A.Y. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport, 1997, 8, 1499-1502.
145. Alvira, D.; Yeste-Velasco, M.; Folch, J.; Verdaguer, E.; Canudas, A.M.; Pallas, M. Comparative analysis of the effects of resveratrol in two apoptotic models: Inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience, 2007, 147, 746-756.
146. Schultes R.E. The virgin field in psychoactive plant research. Bol Mus Emilio Goeldi Ser Bot., 1990, 6(1), 7-82.